|
|
Article: FDA Approval for Starlix Received.
- Article from:
- Drug Week
- Article date:
- January 19, 2001
- Author:
CopyrightCOPYRIGHT 2001 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2001 JAN 19 -- (NewsRx.com) -- Novartis Pharmaceuticals Corp., East Hanover, New Jersey, received marketing approval from the U.S. Food and Drug Administration (FDA) for Starlix (nateglinide) for the treatment of type 2 diabetes.
Starlix, a D-phenylalanine (amino-acid) derivative, is the first in a class of drugs for type 2 diabetes. It is indicated for use as both monotherapy and in combination with metformin, another oral antidiabetic medication, in patients whose blood glucose (sugar) is not controlled by diet and exercise.
Type 2 diabetes is a disease in which the body does not produce or properly use a hormone called insulin that is responsible for ...